Chemotherapy and All-Trans Retinoic Acid in Patients >60 Years with Acute Myeloid Leukemia: First Results of the Multicenter Treatment Trial AML HD98-B
暂无分享,去创建一个
S. Fröhling | K. Döhner | R. Schlenk | H. Döhner | K. Götze | A. Glasmacher | A. Ho | U. Gunzer | F. Hartmann | R. Haas | W. Grimminger | W. Weber | F. D. Valle | J. T. Fischer | C. Weber
[1] P F Thall,et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. , 1999, Blood.
[2] J. Miguel,et al. Incidence, Clinical Features, and Outcome of AllTrans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia , 1998 .
[3] M. Minden,et al. Phosphorylation of BCL-2 after exposure of human leukemic cells to retinoic acid. , 1998, Blood.
[4] P. Fenaux,et al. Retinoic Acid Syndrome , 1998, Drug safety.
[5] P. Allen,et al. Modulation of idarubicin-induced apoptosis in human acute myeloid leukemia blasts by all-trans retinoic acid, 1,25(OH)2 vitamin D3, and granulocyte-macrophage colony-stimulating factor. , 1997, Blood.
[6] C. Bloomfield,et al. All-trans-retinoic acid in acute promyelocytic leukemia. , 1997, The New England journal of medicine.
[7] M. Slovak,et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.
[8] E. Pogliani,et al. Thrombotic complications in acute promyelocytic leukemia during all-trans-retinoic acid therapy. , 1997, Acta haematologica.
[9] Y-M Zhu,et al. Down‐regulation of bcl‐2 in AML blasts by all‐trans retinoic acid and its relationship to CD34 antigen expression , 1996, British journal of haematology.
[10] F. Mandelli,et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. , 1996, Blood.
[11] Zhen-yi Wang,et al. [Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia]. , 1997, Zhonghua nei ke za zhi.
[12] M. Minden,et al. Post-transcriptional regulation of bcl-2 in acute myeloblastic leukemia: significance for response to chemotherapy. , 1996, Leukemia.
[13] O. Garson,et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. , 1996, Blood.
[14] E. Estey,et al. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. , 1996, Leukemia & lymphoma.
[15] M. Minden,et al. Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the Ara-C sensitivity of leukemic stem cells. , 1995, Leukemia.
[16] G. Marit,et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. , 1995, Leukemia.
[17] J. Bennett,et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). , 1995, Blood.
[18] M. Tribalto,et al. All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of 'poor prognosis' acute myeloid leukemia. , 1995, Leukemia.
[19] Stephen L. George,et al. Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia , 1995 .
[20] R. Bouabdallah,et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. , 1995, The New England journal of medicine.
[21] G. Núñez,et al. Regulation and function of Bcl-2 during differentiation-induced cell death in HL-60 promyelocytic cells. , 1995, The American journal of pathology.
[22] N. Bown,et al. De novo acute myeloid leukaemia in patients over 55-years-old: a population-based study of incidence, treatment and outcome. Northern Region Haematology Group. , 1995, Leukemia.
[23] M. Minden,et al. Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia. , 1994, Leukemia.
[24] R. Mayer,et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.
[25] N. Tsukada,et al. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. , 1994, Leukemia.
[26] C. Bloomfield,et al. Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. , 1994, Cancer genetics and cytogenetics.
[27] P. Fenaux,et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group , 1993 .
[28] M. Minden,et al. Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside. , 1993, Leukemia.
[29] R. Mayer,et al. The approach to the elderly patient with acute myeloid leukemia. , 1993, Hematology/oncology clinics of North America.
[30] J. A. Liu Yin,et al. ACUTE MYELOID LEUKAEMIA IN THE ELDERLY: BIOLOGY AND TREATMENT , 1993, British journal of haematology.
[31] C. Tangen,et al. A Southwest Oncology Group study , 1993 .
[32] N. Gattermann,et al. Age‐related incidence and other epidemiological aspects of myelodysplastic syndromes , 1992, British journal of haematology.
[33] R. Warrell,et al. The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia , 1992, Annals of Internal Medicine.
[34] H. Tilly,et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] B. Löwenberg,et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] R. Beuscart,et al. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases , 1989, British journal of haematology.
[37] D. Golde,et al. Treatment of acute myelogenous leukemia in the elderly. , 1989, Seminars in oncology.
[38] Edward J. Lee,et al. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. , 1989, Blood.
[39] M. Oken,et al. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia , 1988, British journal of haematology.
[40] R. Gray,et al. PRINCIPAL RESULTS OF THE MEDICAL RESEARCH COUNCIL'S 8th ACUTE MYELOID LEUKAEMIA TRIAL , 1986, The Lancet.
[41] J. Armitage,et al. Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases , 1985, Cancer.
[42] H. Brincker. Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission. , 1985, Cancer treatment reports.